Research ArticleCancer

EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy

Sci. Signal.  15 Dec 2009:
Vol. 2, Issue 101, pp. ra82
DOI: 10.1126/scisignal.2000446

Log in to view full text

As a service to the community, AAAS/Science has made this article free with registration.

Cited By...

Navigate This Article